XNASGNPX
Market cap7mUSD
Dec 27, Last price
0.88USD
1D
-1.65%
1Q
135.93%
IPO
-99.51%
Name
Genprex Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.77%
Rev. gr., 5y
%
Revenues
0k
Net income
-31m
L+4.74%
CFO
-25m
L+39.15%
Earnings
Mar 31, 2025
Profile
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 31,076 | 47,636 | 19,601 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (31,076) | (47,636) | (19,601) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 5,722 | (5) | |||||||
Tax Rate | |||||||||
NOPAT | (31,076) | (53,358) | (19,596) | ||||||
Net income | (30,860) 4.74% | (29,463) 50.39% | (19,590) 9.30% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 10,593 | 6 | 25,678 | ||||||
BB yield | -84.19% | -0.01% | -41.62% | ||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 443 | ||||||||
Net debt | (6,738) | (20,954) | (38,629) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (24,739) | (17,779) | (14,285) | ||||||
CAPEX | (71) | (60) | |||||||
Cash from investing activities | (71) | 98 | (84) | ||||||
Cash from financing activities | 10,593 | 6 | 25,678 | ||||||
FCF | (31,060) | (53,333) | (16,660) | ||||||
| Balance | |||||||||
Cash | 6,738 | 20,954 | 38,629 | ||||||
Long term investments | |||||||||
Excess cash | 6,738 | 20,954 | 38,629 | ||||||
Stockholders' equity | (133,687) | (102,780) | (77,970) | ||||||
Invested Capital | 141,103 | 125,054 | 119,247 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 1,368 | 1,199 | 1,177 | ||||||
Price | 9.20 -84.14% | 58.00 10.69% | 52.40 -68.43% | ||||||
Market cap | 12,583 -81.90% | 69,533 12.70% | 61,697 -58.15% | ||||||
EV | 5,846 | 48,578 | 23,069 | ||||||
EBITDA | (31,061) | (47,610) | (19,578) | ||||||
EV/EBITDA | |||||||||
Interest | 18,108 | ||||||||
Interest/NOPBT | |||||||||